Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-564 adjuvant pembrolizumab after nephrectomy for renal cell carcinoma
NL-OMON60607Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Pembrolizumab with Placebo (2 arms). Primary endpoint: Disease-free Survival (DFS) as Assessed by the Investigator. Started May 2019; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON60607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60607.